Skip to content
value.today

Flexion Therapeutics Inc

🇺🇸 Woburn, Massachusetts, USABiotechnologyFounded 2007

Formerly FLEXION DEVELOPMENT PARTNERS, INC.

Total raised
$20 M
1 round on record
Latest round
$20 M
Dec 2012
First round on record
Dec 2012
Today
Private
No later event on record

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Flexion Therapeutics Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2012$20 MNo. 1$10 to $50 million

Flexion Therapeutics Inc: Raise no. 1, Dec 2012

Investors in this round

7 investors had bought by the notice of Dec 14, 2012: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Flexion Therapeutics Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $20 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arthur Fratamico · Executive Officer
  • Michael Clayman · Executive Officer, Director
  • Neil Bodick · Executive Officer
  • Alan Milinazzo · Director
  • Andrew Schwab · Director
  • Bradley Bolzon · Director
  • Elaine Jones · Director
  • Heath Lukatch · Director
  • Patrick Mahaffy · Director
  • Rafaele Tordjman · Director
  • Samuel Colella · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Clayman, President and CEO. Source: SEC Form D, newest notice filed Dec 14, 2012. Read the notice at the SEC.

equitySEC
Sep 2009$20 MIssued in a merger or acquisition$10 to $50 million

Flexion Therapeutics Inc: Private sale, Sep 2009

Investors in this round

19 investors had bought by the notice of Oct 15, 2009: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Flexion Therapeutics Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $43 M offered; $23 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Clayman · Executive Officer, Director
  • Neil Bodick · Executive Officer
  • Bradley Bolzon · Director
  • Rafaele Tordjman · Director
  • Samuel Colella · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes the value of certain shares of the common and preferred stock of Flexion Therapeutics AG, which were exchanged as consideration for a portion of the securities reported herein.”
  • On a merger: “The reported transaction includes an exchange of outstanding shares of common or preferred stock of Flexion Therapeutics AG by the holders thereof for an equal number of shares of common or preferred stock of the Issuer.”

Signed by Michael Clayman, Ceo. Source: SEC Form D, newest notice filed Oct 15, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Flexion Therapeutics Inc chose not to state its revenue in its newest notice of a funding round (Dec 2012).

    SEC Form D · Dec 2012

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2012

That is all the official record says: Flexion Therapeutics Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: its website did not answer.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Flexion Therapeutics Inc
InvestorKindAmountRoundRoleSource
5am Co-Investors II LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
5AM Ventures II LPVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Pfizer IncFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Sofinnova Partners SASFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Versant Development Fund III, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Versant Side Fund III, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Versant Venture Capital III, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 7 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Flexion Therapeutics Inc
NameRoleNamed in
Arthur FratamicoExecutive officerDec 2012
Michael ClaymanExecutive officerDec 2012
Neil BodickExecutive officerDec 2012
Alan MilinazzoDirectorDec 2012
Andrew SchwabDirectorDec 2012
Bradley BolzonDirectorDec 2012
Elaine JonesDirectorDec 2012
Heath LukatchDirectorDec 2012
Michael ClaymanDirectorDec 2012
Patrick MahaffyDirectorDec 2012
Rafaele TordjmanDirectorDec 2012
Samuel ColellaDirectorDec 2012

About

American biotechnology company.